Float Short %

2.07

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

0.02

EPS Last/This Y

0.36

EPS This/Next Y

0.19

Price

1.32

Target Price

3.6

Analyst Recom

Performance Q

22.43

Relative Volume

0.35

Beta

1.63

Ticker: CUE

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	CUE	1.03	0.07	5.00	2293
2024-12-20	CUE	1.03	0.07	0.00	2293
2024-12-23	CUE	1.04	0.09	999.99	1653
2024-12-24	CUE	1.01	0.09	999.99	1653
2024-12-26	CUE	1.07	0.10	0.04	1660
2024-12-27	CUE	1.06	0.10	0.04	1660
2024-12-30	CUE	1.02	0.10	0.00	1666
2024-12-31	CUE	1.08	0.10	0.80	1672
2025-01-02	CUE	1.07	0.11	0.00	1698
2025-01-03	CUE	1.39	0.11	0.00	1699
2025-01-06	CUE	1.74	0.10	0.00	1777
2025-01-07	CUE	1.6	0.09	0.43	1980
2025-01-08	CUE	1.44	0.10	0.06	1968
2025-01-09	CUE	1.45	0.10	0.06	1968
2025-01-10	CUE	1.51	0.10	6.14	1970
2025-01-13	CUE	1.34	0.12	0.73	2018
2025-01-14	CUE	1.21	0.12	0.50	1980
2025-01-15	CUE	1.3	0.12	0.00	1975
2025-01-16	CUE	1.26	0.12	17.67	1981
2025-01-17	CUE	1.32	0.24	0.00	2156
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	CUE	1.02	50.0	-	-0.76
2024-12-20	CUE	1.03	50.0	-	-0.76
2024-12-23	CUE	1.04	50.0	-	-0.76
2024-12-24	CUE	1.01	50.0	-	-0.76
2024-12-26	CUE	1.08	50.0	-	-0.76
2024-12-27	CUE	1.05	50.0	-	-0.76
2024-12-30	CUE	1.02	50.0	-	-0.76
2024-12-31	CUE	1.08	50.0	-	-0.76
2025-01-02	CUE	1.08	50.0	-	-0.76
2025-01-03	CUE	1.40	50.0	-	-0.76
2025-01-06	CUE	1.74	50.0	-	-0.76
2025-01-07	CUE	1.59	50.0	-	-0.76
2025-01-08	CUE	1.45	50.0	-	-0.76
2025-01-09	CUE	1.45	50.0	-	-0.76
2025-01-10	CUE	1.50	50.0	-	-0.76
2025-01-13	CUE	1.34	50.0	-	-0.76
2025-01-14	CUE	1.21	50.0	-	-0.76
2025-01-15	CUE	1.30	50.0	-	-0.76
2025-01-16	CUE	1.27	50.0	-	-0.76
2025-01-17	CUE	1.32	50.0	-	-0.76
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	CUE	7.15	0.42	1.60
2024-12-20	CUE	7.15	0.42	1.60
2024-12-23	CUE	7.22	0.42	1.60
2024-12-24	CUE	6.81	0.42	1.60
2024-12-26	CUE	6.95	0.42	1.71
2024-12-27	CUE	6.60	0.42	1.71
2024-12-30	CUE	7.02	0.36	1.71
2024-12-31	CUE	7.02	0.36	1.71
2025-01-02	CUE	6.28	0.36	1.71
2025-01-03	CUE	6.74	0.36	1.71
2025-01-06	CUE	5.21	0.36	1.71
2025-01-07	CUE	5.21	0.36	1.71
2025-01-08	CUE	6.74	0.36	1.71
2025-01-09	CUE	6.74	0.36	1.71
2025-01-10	CUE	6.74	0.36	1.71
2025-01-13	CUE	6.74	0.36	2.07
2025-01-14	CUE	6.74	0.36	2.07
2025-01-15	CUE	6.74	0.36	2.07
2025-01-16	CUE	6.74	0.36	2.07
2025-01-17	CUE	6.74	0.36	2.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

6.74

Institutional Transactions

0.36

Beta

1.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.8

Max Drawdown 5-Year %

-98.5

Target Price

3.6

P/E

Forward P/E

PEG

P/S

8.71

P/B

3.11

P/Free Cash Flow

EPS

-0.91

Average EPS Est. Cur. Y

-0.76

EPS Next Y. (Est.)

-0.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-468.02

Relative Volume

0.35

Return on Equity vs Sector %

-195

Return on Equity vs Industry %

-182.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

Cue Biopharma, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 53

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

stock quote shares CUE – Cue Biopharma Inc Stock Price stock today

news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CUE – Cue Biopharma Inc yahoo finance google finance

stock history CUE – Cue Biopharma Inc invest stock market

stock prices CUE premarket after hours

ticker CUE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CUE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y